Inozyme Pharma, Inc. announced changes to its scientific advisory board (SAB), including the addition of three leading key opinion leaders with specific expertise in the company’s lead indications: W Charles O’Neill IV, M.D., Director of the Ultrasonography Program in the Renal Division at Emory University School of Medicine; Jouni Uitto, M.D., Ph.D., Professor of Dermatology and Cutaneous Biology, and Biochemistry and Molecular Biology, and Chair of the Department of Dermatology and Cutaneous Biology at The Sidney Kimmel Medical College at Thomas Jefferson University, in Philadelphia, Pennsylvania; Paul B. Yu, M.D., Ph.D., Section Head of Cardiovascular Life Sciences at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School. David Thompson, M.A., M.S., Ph.D., a senior adviser to Inozyme, who served as Inozyme’s Senior Vice President and Chief Scientific Officer from 2018-2020, will also be joining the SAB. Enrique M. De La Cruz, Ph.D., Jon S. Morrow, M.D., Ph.D., and Mark A. Lemmon, Ph.D. are stepping down from the SAB, effective immediately.